---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000005"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:41:45.365090+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q4 INGREZZA sales $399M; guides FY23 INGREZZA $1.67-1.77B

## Summary
- Q4 2022 INGREZZA net product sales $399M (+33% YoY); full year $1.43B.
- GAAP net income $89M ($0.88 diluted EPS) vs loss year-ago; non-GAAP net income $125M ($1.24 EPS).
- FY2023 INGREZZA sales guidance $1.67-1.77B (tardive dyskinesia only); GAAP R&D $550-580M, SG&A $850-870M.
- PDUFA date Aug 20, 2023 for valbenazine in Huntington chorea; crinecerfont registrational studies enrollment complete.
- Acquired Diurnal Group (~$55M) Nov 2022; entered Voyager partnership for GBA1 gene therapy Jan 2023.

## SEC filing metadata
- accession: 0000914475-23-000005
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/0000914475-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/nbix-20230206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000005
- JSON: https://secwatch.observer/filing/0000914475-23-000005.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000005.txt

## Key facts
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On February 6, 2023, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/0000914475-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.